Our stochastic solvers were tasked with finding the most soluble (% PEG) variants of an mAb antibody line developed by MedImmune, an AstraZeneca company. We have identified mutants with highly reduced self-aggregation propensity and detected rare amino acid occurrences, which lead to specific protein-protein interactions.
*The remainder of mAb sequence has been obscured for data confidentiality reasons.
Your protein — specific AI is deployed in an encrypted container, receives CPU and GPU allocation, and we provide your team with an instant access and customized User Experience.
Your protein — specific AI is deployed in an encrypted container and is installed in your lab on a barebone HPC solution for maximum performance and security.